[go: up one dir, main page]

PE20120425A1 - Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga - Google Patents

Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga

Info

Publication number
PE20120425A1
PE20120425A1 PE2011001368A PE2011001368A PE20120425A1 PE 20120425 A1 PE20120425 A1 PE 20120425A1 PE 2011001368 A PE2011001368 A PE 2011001368A PE 2011001368 A PE2011001368 A PE 2011001368A PE 20120425 A1 PE20120425 A1 PE 20120425A1
Authority
PE
Peru
Prior art keywords
protein
type
shiga toxin
seq
stx2
Prior art date
Application number
PE2011001368A
Other languages
English (en)
Inventor
Alison O'brien
Angela Melton-Celsa
Michael Smith
James Sinclair
Original Assignee
Jackson H M Found Military Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jackson H M Found Military Med filed Critical Jackson H M Found Military Med
Publication of PE20120425A1 publication Critical patent/PE20120425A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

REFERIDO A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN VEHICULO FARMACEUTICAMENTE ACEPTABLE Y UN POLIPEPTIDO QUE COMPRENDE: I) SEC ID NO:1, II) SEC ID NOS: 1 Y 2 O; III) SEC ID NOS: 1, 2 Y 3 Y UN ANDAMIO DE LA PROTEINA NO-Stx2, DONDE DICHAS SECUENCIAS SE INSERTAN DENTRO DE DICHO ANDAMIO. DICHO POLIPEPTIDO ANTI-Stx2 SE UNE ESPECIFICAMENTE AL EPITOPE 11E10 DE LA PROTEINA Stx2 TIPO 2 DE LA TOXINA SHIGA, SIENDO UTIL EN EL TRATAMIENTO DE SINDROME UREMICO HEMOLITICO ASOCIADA CON LA INFECCION E. COLI O S. DYSENTERIAE
PE2011001368A 2009-01-23 2010-01-21 Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga PE20120425A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14689209P 2009-01-23 2009-01-23
US21008209P 2009-03-13 2009-03-13

Publications (1)

Publication Number Publication Date
PE20120425A1 true PE20120425A1 (es) 2012-05-03

Family

ID=42356196

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001368A PE20120425A1 (es) 2009-01-23 2010-01-21 Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga

Country Status (16)

Country Link
US (2) US8969529B2 (es)
EP (1) EP2381954B8 (es)
JP (1) JP5773886B2 (es)
KR (1) KR101832499B1 (es)
CN (1) CN102292098A (es)
AR (1) AR075047A1 (es)
AU (1) AU2010206800B2 (es)
BR (1) BRPI1007230B1 (es)
CA (1) CA2748873C (es)
CL (1) CL2011001769A1 (es)
ES (1) ES2614803T3 (es)
MX (1) MX2011007866A (es)
NZ (1) NZ593926A (es)
PE (1) PE20120425A1 (es)
RU (1) RU2011126896A (es)
WO (1) WO2010085539A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229045A1 (en) * 2001-02-01 2002-08-07 Institut Curie Universal carrier for targeting molecules to Gb3 receptor expressing cells
WO2007124133A2 (en) 2006-04-20 2007-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on shiga toxin type 1 protein
AU2010206800B2 (en) 2009-01-23 2016-06-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on Shiga toxin type 2 protein
US9310368B1 (en) * 2012-09-28 2016-04-12 The United States Of America, As Represented By The Secretary Of Agriculture High affinity monoclonal antibodies for detection of Shiga toxin 2 (STX2)
US9513287B1 (en) * 2012-09-28 2016-12-06 The United States Of America, As Represented By The Secretary Of Agriculture High affinity monoclonal antibodies for detection of shiga toxin 2
CA2902324A1 (en) * 2013-03-12 2014-10-09 Molecular Templates, Inc. Cd20-binding immunotoxins for inducing cellular internalization and methods using same
CN103343164B (zh) * 2013-06-17 2016-05-18 武汉轻工大学 产志贺毒素大肠杆菌多重pcr检测方法、试剂盒及应用
RU2573924C2 (ru) * 2013-07-11 2016-01-27 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) НЕТОКСИЧНЫЙ РЕКОМБИНАНТНЫЙ ШИГА ТОКСИН 2-ГО ТИПА (Stx2)
IL287490B (en) * 2014-01-27 2022-08-01 Molecular Templates Inc Shiga toxin nonvaccine effector subunit-containing polypeptides for mammalian applications
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
CN113831416A (zh) * 2014-06-11 2021-12-24 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
CN104558167B (zh) * 2014-12-26 2017-12-26 江苏省疾病预防控制中心 检测i型志贺毒素双抗夹心法酶联免疫试剂盒及其应用
ES2856457T3 (es) 2015-02-05 2021-09-27 Molecular Templates Inc Moléculas de unión a CD20 multivalentes que comprenden regiones efectoras de una subunidad de toxina shiga y composiciones enriquecidas de estas
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA2984635A1 (en) 2015-05-30 2016-12-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
AU2018213194B2 (en) 2017-01-25 2023-01-12 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes
AU2019257343A1 (en) 2018-04-17 2020-09-10 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
CN115856296B (zh) * 2022-12-16 2023-07-25 华北理工大学 抗志贺氏菌的单克隆抗体及其检测中的应用
CN120647752B (zh) * 2025-08-19 2025-10-28 中国人民解放军军事科学院军事医学研究院 一种抗ⅱ型志贺毒素的单克隆抗体及其相关产品和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5164298A (en) 1988-06-24 1992-11-17 Hsc Research Development Corporation Verocytotoxin receptor assay
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5552144A (en) * 1992-01-22 1996-09-03 Microcarb, Inc. Immunogenic shiga-like toxin II variant mutants
US5747272A (en) 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
US5968894A (en) 1994-02-22 1999-10-19 Lingwood; Clifford A. Verotoxin pharmaceutical compositions and medical treatments therewith
AR010218A1 (es) 1996-09-10 2000-06-07 Military Henry M Jackson Foundation For The Advancement Of Una familia de proteinas bacterianas multi-unidad
US20020160005A1 (en) * 1996-11-15 2002-10-31 Trustees Of Tufts College Human neutralizing antibodies against hemolytic urmec syndrome
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
WO1998020903A1 (en) 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20030170248A1 (en) 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
CA2328485C (en) 1998-05-20 2011-05-03 Teijin Limited Humanized antibodies that recognize verotoxin ii and cell line producing same
EP1648501B1 (en) 2003-07-21 2011-04-06 Intervet International BV Hybrid toxins comprising shiga-like toxin subunits fused to escherichia coli heat labile enterotoxin subunits and vaccines thereof
WO2005052158A1 (en) 2003-11-28 2005-06-09 National Research Council Of Canada Anticarcinoma antibidies and uses thereof
AU2005210695A1 (en) 2004-02-06 2005-08-18 Nymox Corporation Humanized anti-AF-20 monoclonal antibody
CA2458084A1 (en) 2004-03-12 2005-09-12 Dalton Chemical Laboratories Inc. Novel process for octreotide synthesis
WO2006091677A1 (en) * 2005-02-22 2006-08-31 Jean Gariepy Yeast strains expressing ribosome-inactivating protein domain and method of using same
ES2532985T3 (es) 2006-02-16 2015-04-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Proteínas quiméricas de toxoide de Shiga
WO2007124133A2 (en) * 2006-04-20 2007-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on shiga toxin type 1 protein
EP2545936A3 (en) 2006-05-31 2013-02-20 Thallion Pharmaceuticals Inc. Methods, compositions, and kits for treating Shiga toxin associated conditions
US20090258010A1 (en) 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions
JP4954293B2 (ja) * 2006-12-29 2012-06-13 オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド 改変毒素を選択および生産する方法、改変毒素を含む複合体、およびそれらの使用
EP2207793A2 (en) 2007-10-08 2010-07-21 Rutgers, The State University Nontoxic shiga-like toxin mutant compositions and methods
CN101314616B (zh) * 2008-05-30 2011-05-11 中国人民解放军第三军医大学 肠出血性大肠杆菌o157:h7志贺毒素ⅱb表位肽及其应用
WO2010030986A2 (en) * 2008-09-12 2010-03-18 Scarab Genomics, Llc Clean genome bactofection
AU2010206800B2 (en) 2009-01-23 2016-06-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on Shiga toxin type 2 protein

Also Published As

Publication number Publication date
KR20110119725A (ko) 2011-11-02
EP2381954B8 (en) 2017-01-25
NZ593926A (en) 2013-03-28
US20110318357A1 (en) 2011-12-29
JP5773886B2 (ja) 2015-09-02
EP2381954A4 (en) 2012-08-01
AR075047A1 (es) 2011-03-02
JP2012515551A (ja) 2012-07-12
BRPI1007230A2 (pt) 2016-02-16
WO2010085539A1 (en) 2010-07-29
AU2010206800B2 (en) 2016-06-30
US8969529B2 (en) 2015-03-03
AU2010206800A1 (en) 2011-07-28
ES2614803T3 (es) 2017-06-02
BRPI1007230B1 (pt) 2019-11-12
MX2011007866A (es) 2011-10-06
EP2381954B1 (en) 2016-11-02
CL2011001769A1 (es) 2012-08-31
CN102292098A (zh) 2011-12-21
EP2381954A1 (en) 2011-11-02
RU2011126896A (ru) 2013-02-27
US20160243210A1 (en) 2016-08-25
CA2748873A1 (en) 2010-07-29
KR101832499B1 (ko) 2018-02-26
CA2748873C (en) 2017-09-12
US9801931B2 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
PE20120425A1 (es) Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga
MX2009010800A (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
PE20120206A1 (es) Variantes de polipeptidos receptores de activina iib
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
PE20121393A1 (es) Analogo peptidico de oxintomodulina
NZ598351A (en) Il-17 binding compounds and medical uses thereof
NZ607069A (en) Modified relaxin polypeptides and their uses
EA201270517A1 (ru) Микобактериальные вакцины
HRP20161458T1 (hr) Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze
PE20081804A1 (es) Polipeptidos del receptor de activina variante y usos de los mismos
AR108277A2 (es) Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas
WO2007091030A3 (en) Peptide sequences and compositions
WO2009038026A1 (ja) Ｃｔｌ誘導剤組成物
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
DOP2009000270A (es) Antagonistas ciclicos de peptido cxcr4
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування
NO20063026L (no) Antistoffer
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
RU2011154363A (ru) Комбинации клад rrgb пневмококков
BR112018073669A2 (pt) proteína de fusão, composição de uma primeira proteína e uma segunda proteína, complexo de uma primeira proteína e uma segunda proteína, polinucleotídeos que codificam uma proteína de fusão, vetor contendo o polinucleotídeo, célula hospedeira contendo o polinucleotídeo, uso de uma proteína de fusão, composição farmacêutica, e composição farmacêutica para uso
MX2008004734A (es) Composicion rica en leucina.
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
MX2010005816A (es) Epítopos de péptido de stat3.
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen

Legal Events

Date Code Title Description
FD Application declared void or lapsed